Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × efgartigimod alfa × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

pembrolizumab 112 Carboplatin 109 Cisplatin 102 Paclitaxel 84 Gemcitabine 79 Specimen Handling 72 Magnetic Resonance Spectroscopy 70 Docetaxel 58 Pemetrexed 52 Dexamethasone 52 Cyclophosphamide 52 Capecitabine 52 Oxaliplatin 51 Radiotherapy 50 Doxorubicin 46 Bevacizumab 45 Rituximab 41 Radiation 41 Fluorouracil 41 durvalumab 40 Leucovorin 37 Lenalidomide 36 Vincristine 35 atezolizumab 33 Etoposide 29 Letrozole 28 130-nm albumin-bound paclitaxel 28 Nivolumab 27 Irinotecan 27 Trastuzumab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07217587 2026-03-13

EPIC

Janssen Research & Development, LLC

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡